Searchable abstracts of presentations at key conferences in endocrinology

ea0035p1060 | Thyroid (non-cancer) | ECE2014

THRB expression is affected by miR-26a and miR-496, but age-associated decrease of the expression of this gene in human peripheral blood mononuclear cells is not dependent on these miRNAs

Pawlik-Pachucka Eliza , Budzinska Monika , Domaszewska-Szostek Anna , Owczarz Magdalena , Gewartowska Magdalena , Kurylowicz Alina , Puzianowska-Kuznicka Monika

Introduction: Decreased function of the thyroid axis during aging is associated with a better functional performance and longer survival. This phenomenon can be a result not only of a lower production of thyroid hormones including bioavailable triiodothyronine, but also of age-associated alterations regarding triiodothyronine receptors.Methods: Functional studies regarding interaction between the 3′UTR of TRβ1 mRNA and in silico-ident...

ea0035p1124 | Thyroid Cancer | ECE2014

Functional analysis of newly discovered microRNA deregulated in papillary thyroid carcinoma

Maciag Monika , Kubiak Anna , Swierniak Michal , Dymecka Kinga , Kolanowska Monika , Koperski Lukasz , Gornicka Barbara , Stachlewska Elzbieta , Jazdzewski Krystian

Introduction: Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy where alterations in the RET/PTC–RAS–BRAF signaling pathway and deregulation of microRNA (miRNA) expression are suggested to be major mechanism of pathogenesis. MicroRNAs are small non-coding RNA molecules that recognize specific sequences in 3′UTR of target gene and prevent from its translation. Our recent deep sequencing studies of thyroid tissue transcriptome revealed a put...

ea0049ep1274 | Thyroid (non-cancer) | ECE2017

Is there a correlation between serum selenium level and the severity of Graves’ orbitopathy?

Palyga Iwona , Gasior-Perczak Danuta , Gadawska-Juszczyk Klaudia , Mikina Estera , Piwowar Monika , Szymonek Monika , Trybek Tomasz , Walczyk Agnieszka , Mezyk Ryszard , Majewska Urszula , Kowalska Aldona

Introduction: Selenium (Se) deficiency is a known risk factor for autoimmune thyroid diseases including Graves’ orbitopathy (GO).Objective: To determine the concentration of Se in serum and to determine the dependency of Se concentration on known markers of disease severity: the TRAB levels and the CAS (clinical activity score) in patients with GO.Material: 64 patients (50 women, 14 men; average age- 54.5 years) with active, m...

ea0041ep1053 | Thyroid (non-cancer) | ECE2016

Can routine steroid cover during radioiodine therapy of patients with Graves’ disease (GD) prevent the onset of de novo Graves’ orbitopathy (GO)?

Kowalska Aldona , Palyga Iwona , Gasior-Perczak Danuta , Mikina Estera , Szymonek Monika , Piwowar Monika , Gadawska-Juszczyk Klaudia , Trybek Tomasz , Mezyk Ryszard , Gozdz Stanislaw

Introduction: Radioiodine therapy is considered as a risk factor for the development of Graves’ orbitopathy (GO) de novo or worsening of pre-existing orbitopathy. This risk is estimated in the available literature as up to 15–20%. Steroid cover is considered to eliminated this risk.Objective: The aim of our study was to established the relationship between the occurrence of GO and treatment with radioiodine. And the analysis of the time of appe...

ea0090p574 | Calcium and Bone | ECE2023

A long and challenging journey from the first non-typical gastrointestinal manifestations to the diagnosis of primary hyperparathyroidism and MEN 1

Kiluk Małgorzata , Łebkowska Agnieszka , Kowalska Irina , Karczewska-Kupczewska Monika

Introduction: Primary hyperparathyroidism (PHPT), as a state of chronic hypercalcemia, can be manifested by non-typical symptoms which can delay the proper diagnosis for many years and lead to serious preventable complications affecting the patient’s quality of life.Case report: A 52-year-old woman with hypertension, thyroid nodular goiter treated with radioactive iodine and a 20-year history of gastric and duodenal ulcerative disease, complicated b...

ea0090p464 | Reproductive and Developmental Endocrinology | ECE2023

Visfatin expression and regulation by E2, P4, hCG and insulin in human placental cells

Dawid Monika , Kurowska Patrycja , Pawlicki Piotr , Kotula-Balak Małgorzata , Milewicz Tomasz , Rak Agnieszka

Introduction: Visfatin belongs to adipokines, i.e. hormones produced mainly by adipose tissue; its expression and role have been described in many organs, where it regulates energy metabolism, insulin resistance and inflammatory reactions. Moreover, the level of visfatin changes during pregnancy and in obese women and those with obesity related pregnancy pathologies: preeclampsia (PE), gestational diabetes (GDM) or intrauterine growth restriction (IUGR) its level increases. Th...

ea0063p1055 | Pituitary and Neuroendocrinology 3 | ECE2019

Quality of life in patients with acromegaly assessed by AcroQoL- first application in South Poland

Przybylik-Mazurek Elwira , Krolak Monika , Joanna Marchlewska , Szlauer Anastazja , Hubalewska-Dydejczyk Alicja

Introduction: Acromegaly is a disease associated with increased secretion of growth hormone and subsequent growth of bones, soft tissues and internal organs. An important factor influencing therapeutic treatment in recent years is the patient’s quality of life associated with the disease. In patients with acromegaly, it is significantly affected by the occurrence of depression and anxiety - agents undergoing treatment, which, however, still appear undiagnosed.<p class...

ea0063ep106 | Pituitary and Neuroendocrinology | ECE2019

Central resistance to thyroid hormone coexisting with autoimmune thyroid disease – case report

Szafraniec-Porada Aneta , Porada Dominik , Lenart-Lipińska Monika , Matyjaszek-Matuszek Beata

Pituitary resistance to thyroid hormone (PRTH) is a rare, genetic cause of hyperthyroidism. It is characterized by a high concentration of free thyroid hormones, coexisting with elevated or normal concentration of thyroid stimulating hormone. The most prevalent features of this syndrome are typical symptoms of hyperthyroidism and goitre. Diagnosis of this condition does not exclude other comorbidities of the thyroid gland, including these of autoimmune origin. We present the c...

ea0049ep144 | Clinical case reports - Thyroid/Others | ECE2017

Insulinoma- from diagnosis to full recovery. Case study

Lewicki Marcin , Urbanczuk Magdalena , Zwolak Agnieszka , Dudzinska Marta , Lenart-Lipinska Monika , Tarach Jerzy S.

Introduction: Insulinoma is a rare form of a functional neuroendocrine tumor with an estimated incidence at 1–2 new cases per million persons per year. This infrequent endocrinopathy, frequently escaping standard disease course, constitutes a diagnostic challenge for every endocrinologist. Successful surgical resection of the lesion is the only available method that ensures patient’s full recovery.Case study: 53 years old patient with complaint...

ea0049ep229 | Bone &amp; Osteoporosis | ECE2017

Association between bone mineral density and muscle strength in patients with Turner syndrome, after consideration of selected hormonal and metabolic parameters

Sowinska-Przepiera Elzbieta , Koziolek Monika , Osowicz-Korolonek Lilianna , Poblocki Jakub , Patalong-Nowak Martyna , Syrenicz Anhelli

Turner syndrome (TS), resulting from complete or partial loss of X chromosome, occurs in 1 per 2000-2500 liveborn female neonates. Most patients with TS, especially those untreated with growth hormone, present with osteoporosis or osteopenia, and are at increased risk of bone fractures. Available evidence suggests that depletion of bone mass may be associated with inadequate level of physical activity, and consequently, with too low muscle mass and strength. The aim of the stu...